BillionToOne reported a major Q1 revenue jump, driven by higher prenatal clinical testing volume and a push to expand utilization of its Unity Aneuploidy screening offering through the newly launched Unity Confirm. The company posted Q1 2026 revenue of $108.4 million, up 84% year over year, and raised full-year revenue guidance to $450 million–$465 million. It said it accessioned 189,000 tests in the quarter, with 188,000 delivered. Unity Confirm is a circulating fetal-cell, non-invasive assay intended to confirm high-risk screening results without moving to invasive procedures such as CVS or amniocentesis. Management expects Confirm volumes to remain low—because fewer than 1% of screened patients are expected to test positive—while using that follow-up pathway to differentiate and increase adoption of the Unity Aneuploidy platform. The company also said it is enrolling a prospective clinical trial comparing Unity Confirm with invasive testing, with results expected over one to three years, and added that initial comparisons showed 100% concordance.